Calidi Biotherapeutics (CLDI) Competitors $2.19 -0.10 (-4.37%) (As of 02:30 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CLDI vs. ELYM, KPTI, ANL, EPRX, ORMP, QNCX, NVCT, CABA, ANVS, and ASRTShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Eliem Therapeutics (ELYM), Karyopharm Therapeutics (KPTI), Adlai Nortye (ANL), Eupraxia Pharmaceuticals (EPRX), Oramed Pharmaceuticals (ORMP), Quince Therapeutics (QNCX), Nuvectis Pharma (NVCT), Cabaletta Bio (CABA), Annovis Bio (ANVS), and Assertio (ASRT). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Eliem Therapeutics Karyopharm Therapeutics Adlai Nortye Eupraxia Pharmaceuticals Oramed Pharmaceuticals Quince Therapeutics Nuvectis Pharma Cabaletta Bio Annovis Bio Assertio Eliem Therapeutics (NASDAQ:ELYM) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment. Which has better earnings & valuation, ELYM or CLDI? Calidi Biotherapeutics has higher revenue and earnings than Eliem Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-6.13Calidi Biotherapeutics$50K486.62-$29.22MN/AN/A Does the media refer more to ELYM or CLDI? In the previous week, Calidi Biotherapeutics had 7 more articles in the media than Eliem Therapeutics. MarketBeat recorded 7 mentions for Calidi Biotherapeutics and 0 mentions for Eliem Therapeutics. Calidi Biotherapeutics' average media sentiment score of 0.31 beat Eliem Therapeutics' score of 0.00 indicating that Calidi Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Eliem Therapeutics Neutral Calidi Biotherapeutics Neutral Which has more risk & volatility, ELYM or CLDI? Eliem Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Does the MarketBeat Community prefer ELYM or CLDI? Eliem Therapeutics received 9 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformEliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% Calidi BiotherapeuticsN/AN/A Do analysts prefer ELYM or CLDI? Calidi Biotherapeutics has a consensus target price of $16.67, suggesting a potential upside of 661.04%. Given Calidi Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Calidi Biotherapeutics is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of ELYM or CLDI? 69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 24.3% of Calidi Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ELYM or CLDI more profitable? Calidi Biotherapeutics' return on equity of 0.00% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% Calidi Biotherapeutics N/A N/A -344.45% SummaryCalidi Biotherapeutics beats Eliem Therapeutics on 10 of the 13 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$24.33M$2.98B$5.10B$20.16BDividend YieldN/A1.91%5.04%3.49%P/E RatioN/A19.4095.1237.74Price / Sales486.62286.461,217.3018.58Price / CashN/A169.3839.4921.28Price / Book-2.494.486.974.65Net Income-$29.22M-$41.63M$118.73M$985.06M7 Day Performance7.35%-3.93%-1.22%1.65%1 Month Performance93.81%-5.61%-3.07%2.32%1 Year PerformanceN/A27.32%32.52%26.39% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics2.5503 of 5 stars$2.19-4.4%$16.67+661.0%N/A$24.33M$50,000.000.0041Gap DownHigh Trading VolumeELYMEliem TherapeuticsN/A$3.25+6.2%N/A+28.0%$96.69MN/A-6.1320KPTIKaryopharm Therapeutics3.9733 of 5 stars$0.77-0.6%$5.00+549.4%-1.5%$96.50M$146.03M0.00380ANLAdlai Nortye2.9505 of 5 stars$2.61+1.2%$9.00+244.8%-70.7%$96.31M$5M0.00127EPRXEupraxia Pharmaceuticals2.4971 of 5 stars$3.48-3.3%$9.00+158.6%N/A$94.93MN/A-5.0329News CoverageGap DownORMPOramed Pharmaceuticals1.478 of 5 stars$2.34+3.5%N/A+4.6%$94.33M$1.34M4.4310News CoverageQNCXQuince Therapeutics2.508 of 5 stars$2.14+16.3%$8.50+297.2%+109.1%$94.16MN/A0.0060NVCTNuvectis Pharma3.3184 of 5 stars$4.86-4.1%$21.00+332.1%-38.8%$93.90MN/A-4.118CABACabaletta Bio2.0358 of 5 stars$1.92-15.0%$27.30+1,321.9%-87.4%$93.85MN/A-0.9550Analyst ForecastHigh Trading VolumeANVSAnnovis Bio1.8748 of 5 stars$6.77+3.5%$32.17+375.1%+8.1%$93.43MN/A0.003ASRTAssertio3.2047 of 5 stars$0.95-0.5%$3.25+243.8%-23.4%$90.27M$152.07M-1.3020Positive News Related Companies and Tools Related Companies Eliem Therapeutics Competitors Karyopharm Therapeutics Competitors Adlai Nortye Competitors Eupraxia Pharmaceuticals Competitors Oramed Pharmaceuticals Competitors Quince Therapeutics Competitors Nuvectis Pharma Competitors Cabaletta Bio Competitors Annovis Bio Competitors Assertio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CLDI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
